lnth-2403
·Code: LNTH-2403
lnth-2403: 1 clinical trial tracked.
lnth-2403 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about lnth-2403, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors
Primary endpoint: To assess the safety and tolerability of a single dose of LNTH-2403
Interventionalopen16 targetStarted 2026-10Completion 2027-101 site · AustraliaRadiopharm Theranostics, Ltd